Opinion of the Transparency Council – ipratropium bromide
At its meeting on 9 June 2025, the Transparency Council adopted opinion No. 106/2025 on the inclusion of medicinal products containing the active substance ipratropium bromide in the list of reimbursable medicinal products for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics